Clinical Trial Update: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for LY3023414 and Prexasertib in metastatic triple-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• LY3023414 (samotolisib)
• Prexasertib (prexasertib)

Snippet

Sponsor: Baylor Research Institute | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-09-11